8-K: Profusa Completes Business Combination, Begins Nasdaq Trading Under PFSA Amidst Going Concern Doubts

Profusa, Inc. has successfully closed its business combination with NorthView Acquisition Corp., marking its public debut on Nasdaq under the ticker PFSA, but faces significant financial challenges including increasing losses and substantial doubt about its ability to continue as a going concern.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corp.) completed its business combination with Profusa, Inc. (California corporation) on July 11, 2025.
• The combined entity, now named Profusa, Inc., will commence trading on Nasdaq under the ticker symbol PFSA on July 14, 2025, with warrants continuing to trade on the OTCID market.
• The transaction valued Profusa at $155 million, with an assumed New Profusa Common Stock value of $10.00 per share.
• In connection with the merger, Profusa issued an initial $10 million principal amount of senior secured convertible notes to an institutional investor for a purchase price of $9 million, with access to a total facility of up to $22.22 million (purchase price up to $20 million).
• Profusa is a clinical-stage digital health and medical technology company developing biosensing solutions, including Lumee Oxygen (CE mark in Europe, launched 2023) and Lumee Glucose (in clinical trials, expected Europe launch 2025).
• The company reported a net loss of $2.7 million for the three months ended March 31, 2025, an increase from $2.4 million for the same period in 2024.
• Cash used in operating activities decreased to $0.5 million in Q1 2025 from $0.7 million in Q1 2024.
• As of March 31, 2025, Profusa had notes and loans payable and interest due of $50.2 million within 12 months and cash of less than $0.1 million ($19,000).
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year, citing the need for additional financing and the inability to conclude that plans will be effectively implemented.

Sentiment

Score: 4

Explanation: While the company successfully completed its business combination and secured initial PIPE funding, significant financial challenges persist, including increasing net losses, very low cash reserves, substantial short-term debt, and a stated 'going concern' doubt. The positive strategic developments are overshadowed by the immediate financial instability and reliance on future capital raises.

Positives

• Successful completion of the business combination with NorthView Acquisition Corp., enabling public listing on Nasdaq.
• Secured initial funding of $9 million from a PIPE transaction, with access to a total facility of up to $20 million, providing capital for transaction costs and future working capital.
• Lumee Oxygen product has received CE mark regulatory approval in Europe and launched in 2023.
• Lumee Glucose, a continuous glucose monitoring system, is in clinical trials and expected to launch in Europe in 2025, targeting a comparable or lower price point than existing systems.
• The company's biosensors are designed for simple hypodermic needle insertion, avoiding surgical implantation, which could enhance market adoption.
• Cash used in operating activities decreased to $0.5 million in Q1 2025 from $0.7 million in Q1 2024, indicating improved operational cash efficiency.
• The business combination is expected to de-risk product development, manufacturing, and commercialization efforts.

Negatives

• Incurred a net loss of $2.7 million for the three months ended March 31, 2025, an increase from $2.4 million for the same period in 2024.
• Reported cash of less than $0.1 million ($19,000) as of March 31, 2025, and $0.2 million ($191,000) as of December 31, 2024, indicating very low liquidity.
• Has $50.2 million in notes and loans payable and interest due within 12 months as of March 31, 2025, posing significant short-term debt obligations.
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year, due to recurring losses and the need for additional financing.
• The ability to refinance current debt or raise additional equity financing is outside of management's control, creating uncertainty regarding the going concern issue.
• PPP Loan 2 of $1.3 million is currently in default due to non-payment, and promissory notes are also in default.
• Net cash provided by financing activities decreased to $0.4 million in Q1 2025 from $0.6 million in Q1 2024.
• The company expects to incur additional expenses operating as a public company, including compliance, insurance, and investor relations.

Risks

• Going Concern Risk: Substantial doubt about the ability to continue as a going concern within one year due to recurring losses and reliance on future financing.
• Financing Risk: Additional funds are necessary for operations and product commercialization, but the ability to refinance current debt or raise additional equity financing is outside of management's control, potentially limiting business objectives.
• Regulatory Approval Risk: Lumee Oxygen requires FDA clearance for U.S. commercialization, and Lumee Glucose needs regulatory approval for launch, with no assurance of obtaining necessary approvals.
• Market Acceptance Risk: Uncertainty regarding market acceptance and successful commercialization of Lumee Oxygen and Lumee Glucose.
• Competition: Operates in a dynamic and highly competitive industry, facing risks from advances in new technologies and industry standards.
• Intellectual Property Risk: Risks related to obtaining and maintaining intellectual property protection and not infringing on the rights of others.
• Economic Instability: Exposure to risks from global economic instability, including high inflation, tightening financial conditions, capital outflows, and increased systemic risk.
• Debt Default Risk: Existing PPP Loan 2 and promissory notes are in default, potentially leading to increased interest rates (24% for PIPE notes upon default) and other penalties.
• Dilution Risk: If additional funds are raised by issuing equity securities, dilution to stockholders may result, and new equity securities may have senior rights.
• Operational Expenses: Expected increase in annual expenses due to operating as a public company (SEC/Nasdaq compliance, insurance, director fees, administrative resources).
• APAC Joint Venture Contingency: The APAC Joint Venture and related funding are subject to signing a License Agreement and Shareholders Agreement, and failure to complete could impact the Tasly Convertible Debt.

Future Outlook

Profusa expects to incur additional expenses as a public company due to compliance with SEC and Nasdaq regulations, increased insurance costs, and investor relations activities. The company anticipates requiring additional financing to fund its operations and planned growth, potentially through public or private equity offerings, debt financings, or credit facilities. Management plans to continue substantial investments in building European and United States commercial infrastructure, enhancing existing products, developing new ones, and pursuing discussions with potential partners in Asia. The launch of Lumee Glucose in Europe is expected in 2025, subject to regulatory approval.

Management Comments

• "In a journey that began over a decade ago, driven by a mission to harness transformative science to positively impact quality of daily living and chronic disease management, we are excited to mark a key milestone of going public and trading on Nasdaq."
• "We believe being a public company better positions us to advance our vision in pioneering tissue-integrating biosensors platform that could function for months at a time, with transformative lower costs, and continuously monitor and transmit body chemistries to smart phone applications, and leveraging the best-in-class data analytics and AI technologies, allowing users and healthcare professionals to make real-time actionable decisions that improve general health or manage a chronic disease such as diabetes or critical limb ischemia (CLI), and peripheral arterial disease (PAD)."
• "Thanks to the support of our dedicated employees, partners and investors for leading us to this exciting moment in our companys history."
• "Our management plans to monitor expenses and obtain additional funds through public or private equity offerings or debt financings, additional credit or loan facilities or a combination of one or more of these funding sources, which is intended to mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the unaudited condensed consolidated financial statements are available to be issued."
• "As the ability to refinance our current debt or raise additional equity financing is outside of our managements control, we cannot conclude that managements plans will be effectively implemented within one year from the date the unaudited condensed consolidated financial statements are available to be issued."

Industry Context

The successful business combination and Nasdaq listing position Profusa to compete in the rapidly evolving digital health and medical technology sectors, particularly in biosensing solutions for chronic disease management. The company's focus on long-lasting, injectable sensors and real-time data aligns with broader industry trends towards less invasive, continuous monitoring and personalized healthcare. However, the industry faces challenges from high inflation and tightening global financial conditions, which could impact capital availability and operational costs for companies like Profusa as they scale commercialization efforts.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million accrued.

Related Party Transactions

• Tasly Convertible Debt: A short-term loan agreement with a related party (Tasly Holding Group) for up to $1.6 million, with $1.6 million borrowed in total.
• Promissory Notes: $0.2 million provided by two company founders in 2010 and 2011; $0.3 million borrowed from two founders in 2022 (of which $0.2 million repaid); $0.3 million from an existing investor and $0.1 million from an unrelated party in 2023. These notes are currently in default.
• As of March 31, 2025, $13.7 million of convertible notes and $9.7 million of senior notes were outstanding with related parties.
• APAC Joint Venture: Expected to be formed with Best Life Technology Ltd, an entity wholly owned and controlled by the Tasly Holding Group (a related party).

Stakeholder Impact

• Shareholders: Significant dilution from the business combination and potential future capital raises. Lock-up agreements for existing Profusa shareholders and NorthView initial stockholders will restrict immediate selling. The going concern risk poses a significant threat to shareholder value.
• Employees: The company expects to hire additional personnel and implement new procedures as a public company, potentially creating new opportunities but also increased administrative burden.
• Customers: Continued development and commercialization of Lumee Oxygen and Lumee Glucose aim to improve health outcomes for patients with conditions like Critical Limb Ischemia and diabetes.
• Creditors: The company has substantial current debt obligations, including defaulted loans, and relies on future financing to meet these obligations, posing a risk to creditors. The PIPE investors have a senior secured convertible note, providing some protection.

Next Steps

• New Profusa Common Stock to begin trading on Nasdaq under PFSA on July 14, 2025.
• New Profusa to file a registration statement for the resale of PIPE Convertible Notes within 20 calendar days after the Closing Date, aiming for effectiveness within 45 days (no later than 60th day).
• Management plans to monitor expenses and obtain additional funds through public or private equity offerings or debt financings.
• Continue substantial investments in building European and United States commercial infrastructure.
• Enhance existing products and develop new ones.
• Continue discussions with potential partners in Asia.
• Lumee Glucose launch expected in Europe in 2025, subject to regulatory approval.
• Company to apply for forgiveness for PPP Loan 2.
• Repay promissory notes in parallel with the closing of the Business Combination.
• Sign and execute a License Agreement and Shareholders Agreement for the APAC Joint Venture.

Key Dates

Recommendation

Keywords

Profusa, NorthView Acquisition Corp, Business Combination, Merger, Nasdaq Listing, PFSA, Digital Health, Medical Technology, Biosensors, Lumee Oxygen, Lumee Glucose, Continuous Glucose Monitoring, CGM, Critical Limb Ischemia, CLI, Peripheral Arterial Disease, PAD, SEC Filing, 8-K, PIPE Financing, Convertible Notes, Going Concern, Clinical Trials, Regulatory Approval, Healthcare Innovation, Biocompatible Sensors